A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The aim of the current study is to determine whether rifaximin or lactulose is more effective
in preventing the development of severe hepatic encephalopathy in hospitalized patients with
cirrhosis and new onset kidney failure.
Subjects will be randomly assigned to one of two treatment groups:
Group A: Lactulose 20g dose titrated to 2-3 soft-formed bowel movements per day Group B:
Rifaximin 550mg tablet twice daily.
Subjects will be followed daily for two weeks or until hospital discharge. Treatment success
is defined as prevention of grade 3 or 4 HE during hospitalization.
Phase:
Phase 3
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health